Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $4.00 price target on the stock.
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
Clearside Biomedical, Inc. (NASDAQ: CLSD) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]